BAY-826 (BAY826) is a novel selective, highly potent, orally available TIE-2 inhibitor (dissociation constant=1.6 nM).

BAY-958 (BAY958, LDC526) is a potent, selective PTEFb/CDK9 inhibitor with IC50 of 5 nM against CDK9/CyclinT1.

Bayer-18 is a selective TYK2 inhibitor, with an IC50 of 18.7nM on TYK2 as measured by TYK2 HTRF assays.

BAZ2-ICR is a selective BAZ2 bromodomain inhibitor (Kd values are 109 and 170 nM for BAZ2A and BAZ2B respectively).

BB-Cl-Amidine is a peptidylarginine deminase (PAD) inhibitor.

BBT594 (NVP-BBT594), is potent and selective inhibitor of RET and JAK2.

BC-1215 (BC1215) is a highly unique, selective E3 ligase F box component Fbxo3 inhibitor with IL1β IC50 of 0.9 ug/mL.

BC-1485 is a first-in-class, small molecule inhibitor of FIEL1 (Fibrosis-inducing E3 ligase 1) that exhibits potent activity toward disrupting FIEL1-directed PIAS4 ubiquitination.

BC-21 (NSC 109268) is a novel small molecule inhibitor that effectively inhibits the β-catenin/Tcf4 interaction with Ki of 6.55 uM.

BC-23 (NSC 45382) is a novel inhibitor of β-catenin/Tcf4 interaction with IC50 of 1.7 uM.

BCI-137 is a chemical compound able to compete with Argonaute 2 miRNAs binding, binds to Ago2 with Kd of 126 uM.

BCL6 inhibitor 14 is a potent BCL-6 inhibitor with FRET IC50 of 63 nM..

BCL6 PROTAC 15 is a novel B-cell lymphoma 6 (BCL6) PROTAC, significantly degrade BCL6 in a number of DLBCL cell lines, but neither BCL6 inhibition nor degradation selectively induces marked phenotypic response.

BCL6-IN-8 (BCL6-i) is a potent, irreversible and cell-active BCL6 inhibitor with inact/KI value of 1.9 × 104 M-1 s-1, targets Cys53 located at the protein-protein interaction interface.

BCM-599 is an efficient HBV capsid assembly inhibitor with in vitro IC50 of 13 uM, shows synergistic inhibitory effects on decreasing viral concentration combined with lamivudine in vivo..

BCX-1470 (BCX1470) is a serine protease inhibitor that inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM).

BD-1047 is a potent, selecitve Sigma 1 receptor (σ1) antagonist with Ki of 0.93 nM.

BDA-366 is a Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.

BDCRB (GW 275175) is a potent and selective inhibitor of human CMV replication by blocking the processing and maturation of viral DNA..

BDP8900 (BDP-8900) is a highly potent and selective Myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with IC50 of 43 nM (MRCKβ), >100-fold selectivity over related ROCK1 or ROCK2.

BDP9066 (BDP-9066) is a highly potent and selective Myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with IC50 of 43 nM, >100-fold selectivity over related ROCK1 or ROCK2.

BDP-NAC is a novel persulfide donor that shows selectivity towards H2 O2 over other potential oxidative or nucleophilic triggers, resulting in the sustained release of the persulfide of N-acetyl cysteine (NAC).